首页> 美国卫生研究院文献>Nanoscale Research Letters >An injectable hybrid nanoparticle-in-oil-in-water submicron emulsion for improved delivery of poorly soluble drugs
【2h】

An injectable hybrid nanoparticle-in-oil-in-water submicron emulsion for improved delivery of poorly soluble drugs

机译:可注射混合的水包油纳米粒子纳米乳剂用于改善难溶性药物的递送

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Poor drugability problems are commonly seen in a class of chemical entities with poor solubility in water and oil, and moreover, physicochemical instability of these compounds poses extra challenges in design of dosage forms. Such problems contribute a significant high failure rate in new drug development. A hybrid nanoparicle-in-oil-in-water (N/O/W) submicron emulsion was proposed for improved delivery of poorly soluble and unstable drugs (e.g., dihydroartemisinin (DHA)). DHA is known for its potent antimalarial effect and antitumor activity. However, its insolubility and instability impose big challenges for formulations, and so far, no injectable dosage forms are clinically available yet. Therefore, an injectable DHA N/O/W system was developed. Unlike other widely-explored systems (e.g., liposomes, micelles, and emulsions), in which low drug load and only short-term storage are often found, the hybrid submicron emulsion possesses three-fold higher drug-loading capacity than the conventional O/W emulsion. Of note, it can be manufactured into a freeze-drying form and can render its storage up to 6 months even in room temperature. The in vivo studies demonstrated that the PK profiles were significantly improved, and this injectable system was effective in suppressing tumor growth. The strategy provides a useful solution to effective delivery of such a class of drugs.
机译:在水和油中溶解性差的一类化学实体中通常会看到较差的可药物性问题,此外,这些化合物的物理化学不稳定性给剂型设计带来了额外的挑战。这些问题在新药开发中造成了很高的失败率。为了改善难溶性和不稳定药物(例如双氢青蒿素(DHA))的递送,提出了一种混合的水包油纳米粒(N / O / W)亚微米乳剂。 DHA以其强大的抗疟疾作用和抗肿瘤活性而闻名。但是,其不溶性和不稳定性给制剂带来了很大的挑战,到目前为止,尚无可临床使用的注射剂型。因此,开发了可注射的DHA N / O / W系统。与其他经常探索的系统(例如脂质体,胶束和乳剂)不同,在该系统中经常发现药物载量低且只能短期保存,而杂化亚微米乳剂的载药量是传统O / O的三倍。 W乳液。值得注意的是,它可以制成冷冻干燥形式,即使在室温下也可以保存长达6个月。体内研究表明,PK曲线显着改善,并且这种注射系统可有效抑制肿瘤生长。该策略为有效交付此类药物提供了有用的解决方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号